The US Food and Drug Administration on 16 April approved a PMA for BAROnova Inc.’s TransPyloric Shuttle (TPS) and its delivery system to treat obesity.
BaroNova’s TransPyloric Shuttle Earns FDA-Approval To Treat Obesity
Patients treated with the TransPyloric Shuttle in the 213-patient ENDObesity II trial lost an average of 9.5% of their body-weight and 30.9% of their excess weight.
More from Approvals
• By
“We believe [the SAPIEN M3] launch alongside PASCAL and EVOQUE will help support the company’s target of $2bn in transcatheter mitral and tricuspid therapies sales by 2030,” noted analysts from Leerink Partners.
• By
Dexcom announced it received US clearance for its 15-day CGM, which has a MARD of 8.0% and is expected to launch in the second half of 2025 to allow for integration with insulin pumps.
• By
A concealed blunt-tip needle that can be inserted into the heart's pericardial space to treat cardiac arrhythmias has received FDA clearance, providing an alternative to catheter-based methods.
• By
The Visby Medical Women’s Sexual Health Test is the first over-the-counter test cleared by the US Food and Drug Administration to detect chlamydia, gonorrhea and trichomoniasis. It delivers results in about 30 minutes.
More from Policy & Regulation
• By
The new telework policy returns to the pre-COVID-19 pandemic standard, but still requires reviewers to be at White Oak for sponsor meetings and divisions to have an in-office presence every day.
• By
The deadline for comments is 30 June 2025
• By
Dexcom announced it received US clearance for its 15-day CGM, which has a MARD of 8.0% and is expected to launch in the second half of 2025 to allow for integration with insulin pumps.